Protagonist Therapeutics Reports FY2025 Loss, Advances Key Pipeline Programs, and Details Takeda Collaboration Opt-Out Strategy

summarizeSummary

Protagonist Therapeutics reported a net loss of $130.1 million for fiscal year 2025, while highlighting significant progress across its clinical pipeline, including NDA submissions for Icotyde and Rusfertide, and plans to exercise an opt-out right in the Takeda collaboration for Rusfertide, potentially yielding substantial future payments.

check_boxKey Events

• FY2025 Financial Results

  Reported a net loss of $130.1 million for fiscal year 2025, compared to a net income of $275.2 million in 2024.

• Strong Cash Position

  Ended fiscal 2025 with $646.0 million in cash, cash equivalents, and marketable securities, sufficient to fund operations for over 12 months.

• Icotyde NDA Submitted

  Janssen Biotech, Inc. (JNJ) submitted New Drug Applications (NDAs) for Icotyde (icotrokinra) to the U.S. FDA in July 2025 and the European Medicines Agency (EMA) in September 2025 for moderate-to-severe plaque psoriasis, with a U.S. launch expected in 2026.

• Rusfertide NDA Submitted & Opt-Out Strategy

  An NDA for rusfertide in polycythemia vera (PV) was submitted to the FDA in December 2025. Protagonist expects to exercise its opt-out right in the Takeda collaboration in Q2 2026, potentially receiving up to $400.0 million in payments and enhanced tiered royalties on worldwide net sales.

auto_awesomeAnalysis

Protagonist Therapeutics filed its annual 10-K report, revealing a net loss of $130.1 million for fiscal year 2025, a significant shift from a net income of $275.2 million in 2024, which was largely driven by collaboration payments. Despite the loss, the company maintains a strong cash position of $646.0 million, which is projected to fund operations for at least the next twelve months. The filing highlights substantial progress in its pipeline, including the submission of New Drug Applications (NDAs) for Icotyde (partnered with JNJ) and Rusfertide (partnered with Takeda). A key strategic development is the company's intent to exercise its opt-out right in the Takeda collaboration for Rusfertide in Q2 2026, which could lead to significant payments totaling up to $400.0 million upon exercise and FDA approval, in addition to enhanced tiered royalties on worldwide net sales. This move indicates confidence in Rusfertide's commercial potential and could substantially bolster future revenue streams. The company also advanced several other programs into or towards Phase 1 clinical studies, demonstrating a robust and active development pipeline.